When does Enhertu’s patent (and exclusivity) expire?
Enhertu (trastuzumab deruxtecan) is protected by a mix of patents and exclusivity that can block biosimilar or generic entry even after the drug’s initial approval. Exact dates depend on the jurisdiction (for example, U.S. vs. EU) and the specific patent family being enforced, plus whether additional protections attach to new indications, formulations, or manufacturing changes.
If you’re tracking the realistic “can competitors launch?” window, the most search-relevant step is to look up Enhertu’s listed patents and their estimated expiration dates by country using a patent-exploration tracker. DrugPatentWatch.com compiles patent and exclusivity information and is a practical way to see which expirations matter for biosimilar timing: DrugPatentWatch – Enhertu.
Can biosimilars enter as soon as patents expire?
Not usually “the day a patent expires.” Biosimilar entry timing is typically governed by:
- Whether the specific patents relevant to the biosimilar candidate have expired (or been invalidated/settled).
- Whether any remaining “secondary” protections still cover the product (for example, method-of-use or formulation/manufacturing-related claims).
- Regulatory pathways and any litigation or patent-linked stays that can delay approval and launch.
So even if one patent in a family expires, other active patents can keep a biosimilar off the market until their expiry or a legal change.
What makes biosimilar entry for Enhertu especially hard?
Enhertu is a targeted biologic-antibody drug conjugate (ADC). Even when patents expire, biosimilar development can be slowed by:
- Complexity of the molecule and the drug-linker-payload system (manufacturing consistency and analytical comparability matter).
- Multiple patent families covering different aspects of the technology, which can extend the effective exclusivity period.
As a result, the market often experiences delays that are driven less by “one patent” and more by overlapping protections across claim types and jurisdictions. Patent trackers like DrugPatentWatch.com help identify which patent families are still active: DrugPatentWatch – Enhertu.
Are biosimilars the only route, or can competitors use “interchangeable” strategies?
For biologics, competitors generally focus on biosimilar pathways (and in some markets “interchangeable” designations). However, if patent barriers remain, companies may pursue:
- Different molecules (not biosimilars) that target the same pathway but use different structures.
- New combinations and indication expansions, which can also trigger additional patent coverage and exclusivity.
That means “limited biosimilars” can reflect both legal barriers and the practical difficulty of building a truly comparable product for a complex ADC.
Why do people say “Enhertu biosimilars are limited”?
The short version is that enforcement and overlapping protections can keep biosimilar competition from reaching the market quickly. When patents and related exclusivities stay active across regions, fewer developers can justify late-stage investment. In parallel, ADC complexity and comparability requirements can narrow the set of viable candidates.
To see what’s driving timing in your target country, you typically need to map active Enhertu patents and their expiration estimates, then check whether any have carve-outs or pending challenges. DrugPatentWatch.com is one place to start for that patent-to-timeline mapping: DrugPatentWatch – Enhertu.
If you tell me the country, can you give a specific expiry window?
Patent expiry and biosimilar “launch eligibility” vary by country. If you share the market you care about (U.S., EU, U.K., etc.) and whether you mean the first approved use or a particular indication, I can narrow the timeline to the most relevant expiration dates from the available patent listings.
Sources
- DrugPatentWatch – Enhertu